These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
460 related articles for article (PubMed ID: 26602222)
1. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Chlebowski RT; Haque R; Hedlin H; Col N; Paskett E; Manson JE; Kubo JT; Johnson KC; Wactawski-Wende J; Pan K; Anderson G Breast Cancer Res Treat; 2015 Dec; 154(3):609-16. PubMed ID: 26602222 [TBL] [Abstract][Full Text] [Related]
2. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Mouridsen HT; Robert NJ Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456 [TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Ingle JN Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884 [TBL] [Abstract][Full Text] [Related]
4. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [TBL] [Abstract][Full Text] [Related]
5. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905 [TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? Baum M Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117 [TBL] [Abstract][Full Text] [Related]
8. Obesity and endocrine therapy: host factors and breast cancer outcome. Goodwin PJ Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Wheler J; Johnson M; Seidman A Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347 [TBL] [Abstract][Full Text] [Related]
10. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Monnier AM Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927 [TBL] [Abstract][Full Text] [Related]
11. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T; Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060 [TBL] [Abstract][Full Text] [Related]
12. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW; Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403 [TBL] [Abstract][Full Text] [Related]
13. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
14. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Buzdar AU; Cuzick J Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122 [TBL] [Abstract][Full Text] [Related]
15. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review. Poole R; Paridaens R Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453 [TBL] [Abstract][Full Text] [Related]
16. The use of aromatase inhibitors in adjuvant therapy for early breast cancer. Jonat W; Hilpert F; Maass N Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():32-8. PubMed ID: 16273366 [TBL] [Abstract][Full Text] [Related]
17. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889 [TBL] [Abstract][Full Text] [Related]
18. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Berry J Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441 [TBL] [Abstract][Full Text] [Related]
19. Update of the BIG 1-98 Trial: where do we stand? Joerger M; Thürlimann B Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548 [TBL] [Abstract][Full Text] [Related]